Recent studies have demonstrated that treatment with small molecule drugs that target HBP lead to increased infiltration of CD8 + T cells, sensitizing pancreatic tumors to anti-PD1 therapy and causing tumor regression and prolonged survival (Sharma et al., 2020). The gene discussed is CD8A; the disease is neoplasm.